Wharton’s Jelly Mesenchymal Stromal Cells and Derived Extracellular Vesicles as Post-Myocardial Infarction Therapeutic Toolkit: An Experienced View

Abstract

Outstanding progress has been achieved in developing therapeutic options for reasonably alleviating symptoms and prolonging the lifespan of patients suffering from myocardial infarction (MI). Current treatments, however, only partially address the functional recovery of post-infarcted myocardium, which is in fact the major goal for effective primary care. In this context, we largely investigated novel cell and TE tissue engineering therapeutic approaches for cardiac repair, particularly using multipotent mesenchymal stromal cells (MSC) and natural extracellular matrices, from pre-clinical studies to clinical application. A further step in this field is offered by MSC-derived extracellular vesicles (EV), which are naturally released nanosized lipid bilayer-delimited particles with a key role in cell-to-cell communication. Herein, in this review, we further describe and discuss the rationale, outcomes and challenges of our evidence-based therapy approaches using Wharton’s jelly MSC and derived EV in post-MI management.

Role of Exosomes in Pharyngucutaneous Fistula After Total Laryngectomy

“…Based on their good physiological characteristics, exosomes have been used in the diagnosis of myocardial infarction, 70,71 psychiatric diseases, 72 cancer, [73][74][75][76][77] spinal cord injury, and wound healing in vivo. 78,79 In vitro, exosomes have been included in drug carriers, 80 where access to the lesion achieves the purpose of treatment through direct injection, intravenous delivery, intraperitoneal injection, and others.…”